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ABSTRACT
Objectives Major histocompatibility complex (MHC)
class II-mediated priming of T and B lymphocytes is a
central element of autoimmunity in systemic lupus
erythematosus (SLE) and lupus nephritis. The cysteine
protease cathepsin S degrades the invariant peptide
chain during MHC II assembly with antigenic peptide in
antigen-presenting cells; therefore, we hypothesised that
cathepsin S inhibition would be therapeutic in SLE.
Methods We developed a highly specific small
molecule, orally available, cathepsin S antagonist,
RO5461111, with suitable pharmacodynamic and
pharmacokinetic properties that efficiently suppressed
antigen-specific T cell and B cell priming in vitro and in
vivo.
Results When given to MRL-Fas(lpr) mice with SLE and
lupus nephritis, RO5461111 significantly reduced the
activation of spleen dendritic cells and the subsequent
expansion and activation of CD4 T cells and CD4/CD8
double-negative T cells. Cathepsin S inhibition impaired
the spatial organisation of germinal centres, suppressed
follicular B cell maturation to plasma cells and Ig class
switch. This reversed hypergammaglobulinemia and
significantly suppressed the plasma levels of numerous
IgG (but not IgM) autoantibodies below baseline,
including anti-dsDNA. This effect was associated with
less glomerular IgG deposits, which protected kidneys
from lupus nephritis.
Conclusions Together, cathepsin S promotes SLE by
driving MHC class II-mediated T and B cell priming,
germinal centre formation and B cell maturation towards
plasma cells. These afferent immune pathways can be
specifically reversed with the cathepsin S antagonist
RO5461111, which prevents lupus nephritis progression
even when given after disease onset. This novel
therapeutic strategy could correct a common
pathomechanism of SLE and other immune complex-
related autoimmune diseases.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a systemic
autoimmune disease affecting young females by
immune complex (IC)-related disease manifestations
such as glomerulonephritis (GN), that is, lupus neph-
ritis.1 2 Patients at risk for progressive tissue damage
are treated with unselective immunosuppressive
drugs such as steroids, cyclophosphamide, mycophe-
nolate mofetil and calcineurin inhibitors, but drug
toxicity and lack of efficacy are often associated with
poor outcomes.3 Novel drugs that interfere with the
disease pathomechanisms more specifically are
needed to improve lupus management.
Major histocompatibility complex (MHC) class
II-mediated priming of (auto-)antigen-specific T and
B cells is the central element of cellular and humoral
(auto-)immunity and has been a target for various
innovative treatment approaches.3 The presentation
of self-antigenic peptides within MHC class II in the
context of Toll-like receptor-dependent costimulation
activates antigen-specific CD4 T helper cells for their
clonal expansion and polarisation into the various
CD4 T cell subsets. These cells then activate antigen-
specific follicular B cells to undergo clonal expansion
inside the germinal centres of the lymphoid follicles.4
The germinal centre environment is also needed for
driving the somatic hypermutation of activated B
cells, which involves affinity maturation and Ig class
switch from immunoregulatory IgM-producing B
cells into high affinity and complement-binding
IgG-antibody-producing plasma cells.4 Subsequently,
IC-related pathologies develop either from the
deposition of circulating IC or from in situ formation
of IC where they trigger tissue inflammation by acti-
vating a number of local innate immunity
pathways.5 6
Cathepsin S (Cat S), a cysteine protease of the
papain family, is expressed in lysosomal/endosomal
compartments of antigen-presenting cells, such as B
cells, macrophages and dendritic cells.7 Inside the B
cells and dendritic cells, Cat S is the single enzyme
that cleaves the Ii p10; a 10 kDa fragment of the
MHC-II-bound invariant chain to form 24 amino acid
CLIP fragments during the assembly of the MHC
class II-α and II-β chains with the antigenic peptide in
the lysosomal/endosomal compartments.8–14 This
process contributes to antigen-induced adaptive
immunity as demonstrated by vaccinating mice with
myelin oligodendrocyte glycoprotein35–55 peptide,
15
bovine type II collagen,15 ovalbumin16 or α-fodrin in
Sjögren’s syndrome,17 even though Cat S was not
required for thyroid-stimulating hormone receptor-
induced autoimmune thyreoditis.18 As, in addition,
Cat S degrades autoantigenic peptides favouring
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autoreactive CD4 T cells to escape thymic selection,19 there is a
robust rationale for Cat S being a mediator of autoimmunity in
SLE.
To address this concept, we first characterised Cat S expres-
sion in female MRL-(Fas)lpr mice with spontaneous SLE. To
study the functional contribution of Cat S and its suitability as a
therapeutic target, we developed a specific, orally available, Cat
S inhibitor that dose-dependently suppresses the proteolytic
activity of murine and human Cat S in vitro and in vivo
(table 1). By treating diseased female MRL-(Fas)lpr mice with
this compound, we not only demonstrate a non-redundant role
of Cat S for IgG autoantibody production but also identify Cat
S as a therapeutic target for systemic lupus and lupus nephritis.
MATERIALS AND METHODS
Generation of the Cat S antagonist RO5461111
RO5461111 (CAS 1252637-46-9) was provided by F. Hoffmann-
La Roche, Ltd., Basel, Switzerland. It is a competitive inhibitor of
the active site of Cat S, and its nitrile function allows covalent
reversible inhibition of Cat S. The synthesis and drug development
of RO5461111 has been described in WO 2010121918.
Recombinant cathepsins were produced in-house or were purchased
from commercial vendors. Enzymatic assays were performed using
the fluorogenic substrate (Z-Val-Val-Arg-AMC for human and
mouse Cat S, human Cat L & Cat B, Z-Leu-Arg-AMC for human
Cat K and Cat V). The generation of fluorescence over 10 min was
measured using 10 μM of substrate and 1 nM of enzyme in the
presence of raising concentrations of RO5461111 to determine
IC50 values. The cellular activity of RO5461111 was tested in B cell
lines of human (RAJI) or mouse (A20) origin by incubating with
increasing concentrations of RO5461111 overnight. Protein
extracts were prepared for detection of p10 upregulation by Cat S
inhibition using western blotting. For the determination of in vivo
enzyme inhibition activity of Cat S by RO5461111, BALB/c mice
were used. After oral dosing of 0.1–100 mg/kg of RO5461111,
mice were sacrificed after 7 h and spleens harvested. Protein extracts
were separated by SDS-gel electrophoresis for the determination of
p10 upregulation by Cat S inhibition as described below. A20 cells
were plated in RPMI-1640 medium at 3×105 cells/mL in 100 mL/
well of a U-bottom 96-well plate. Compounds were added and cells
incubated for 1 h before the addition of ovalbumin to a final con-
centration of 5 mg/mL (Sigma-Aldrich). After 16 h, the cells were
washed three times with phosphate-buffered saline (PBS) and
2×105 DO11.10 T cell hybridoma cells/mL were added. After
24 h, interleukin 2 (IL-2) production was measured as a read out
parameter of antigen-specific T cell activation by Luminex single
bead analysis using two anti-IL-2 antibodies (BD, cat. nos.: 554424
and 554426).
Mice and experimental protocol
Eight-week-old female MRL-Fas(lpr) mice were obtained from
Harlan Winkelmann (Borchen, Germany) and kept under
pathogen-free and normal housing conditions in a 12 h light and
dark cycle. At the age of 12 weeks, proteinuria and serum creatin-
ine were assessed and only mice with either proteinuria and/or ele-
vated serum creatinine levels were randomised to receive from
week 12 either a medicated diet formulated by mixing the Cat S
inhibitor (R05461111, 262.5 mg/kg chow) or standard diet
(vehicle) (n=15 in each group). The mice consumed approxi-
mately 5 g food per day (1.31 mg drug per day) with no difference
in food intake or body weight between the two groups. All mice
were sacrificed by cervical dislocation at the end of week 20 of
age. Blood and urine samples were collected from each mouse at
the start of the study (baseline) during the fourth week of the
study and at the end of the study period (eighth week). For sheep
IgG immunisation study, 8-week-old male C57BL/6 mice were
immunised on day 0 subcutaneously (s.c.) in both hind foot pads
with 10 mg of sheep IgG ( Jackson ImmunoResearch Laboratories,
Suffolk, UK) in an emulsion containing 50% (v/v) sterile PBS and
50% (v/v) complete Freund’s adjuvant (Sigma). On day 7, mice
were re-challenged with 10 mg of sheep IgG using retro-orbital
injection. Ten days after immunisation, the mice were sacrificed by
cervical dislocation to collect blood and spleen tissue. All experi-
ments were performed according to German animal protection
laws and had been approved by the local government authorities.
Morphological evaluation
Kidneys and lungs from all mice were fixed in 10% buffered for-
malin, processed and embedded in paraffin. Two-micrometer par-
affin sections for periodic acid–schiff stains were prepared from
lung and kidney tissue samples following routine protocols as
described.20 The severity of the renal lesions was graded using the
indices for activity and chronicity as described for human lupus
nephritis.21 Cat S, IgG and Mac-2 immunostaining was performed
as described using the following primary antibodies: anti-cathepsin
S antibody (abcam, Cambridge, UK), antimouse Mac-2 (Cedarlane
Laboratories, Ontario, Canada) and antimouse IgG (Caltag
Laboratories). Spleen sections were also stained with IgG (BD
Pharmingen) and the lectin peanut agglutinin (PNA) as
described,22 which binds to immature, proliferating B cells within
germinal centres. Immunostaining was performed on frozen sec-
tions using antimouse C3c (Nordic Immunological Laboratories).
The severity of the peribronchial inflammation was graded semi-
quantitatively from 0 to 4 as described.23 In situ hybridisation was
performed using Quantigene ViewRNA ISH Tissue Assay Kit
(Affymetrix/Panomics Solutions). The assay uses proprietary
chemistry for the target-specific probe sets and branched-DNA
signal amplification for detection of specific signal. Specific probe
sets for mouse CTSS and EMR1 mRNAs were designed by
Affymetrix based on the following sequences: NM_001267695
and NM_021281 for CTSS, and NM_010130 for EMR1. Tissue
sections of 4 mm prepared from formalin fixed paraffin embedded
(FFPE) mouse kidney and spleen tissues were mounted onto
microslides (X-tra Adhesive, Leica) and processed according to
manufacturer’s instructions. Briefly, slides were baked for 1 h at
60°C (Thermobrite, Abbott Molecular) and fixed in 10% formal-
dehyde for 1 h at RT. Deparaffinisation was achieved using
Histo-Clear reagent (National Diagnostics). Prehybridisation con-
ditions were found to be optimal with 10 min of boiling at 95°C
and 10 min incubation at 40°C with Protease QF diluted 1/100×.
Target probe set hybridisation (type 6 or type 1 probe sets for blue
or red staining, respectively) was carried out for 2 h at 40°C.
Hybridised probes were amplified using PreAmplifier Mix QTand
Amplifier Mix QT oligonucleotides incubating slides at 40°C for
25 and 15 min, respectively. Slides were then exposed to Label
Probe conjugated with alkaline phosphatase (Label Probe 6-AP or
1-AP for blue or red staining, respectively) for 15 min at 40°C and
to Fast Blue or Fast Red substrates at RT for 15 min or at 40°C for
30 min, respectively. When 2-Plex assays were carried out, incuba-
tions with Label Probe 6-AP and Fast Blue substrate were carried
out before incubations with Label Probe 1-AP and Fast Red sub-
strate. Slides were counterstained with Gill’s haematoxylin stain
for 5–10 s at RT. In-between each incubation described, slides
were washed 2–3 times in washing solution, PBS or water accord-
ing to the manufacturer’s instructions. Imaging was performed
under brightfield with a Zeiss microscope equipped with an
AxiocamMRC camera.
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Plasma cytokines
The plasma levels of IL-10 and IL-12p40 were measured using
commercial kits from BD (BD Biosciences, San Diego,
California, USA) according to the manufacturer’s instructions.
Plasma levels of IL-2, interferon γ (IFN-γ) and tumour necrosis
factor α (TNF-α) were measured using commercial kits from
BioLegend (Fell, Germany). Absorbance was read using Tecan
Microplate Reader (Biotek, Winooski, Vermont, USA).
Western blotting
Invariant chain p10 accumulation was detected in spleen tissue
by western blotting. Spleen tissues from vehicle and treated
animals were homogenised in RIPA buffer with protease inhibi-
tors. Lysates were electrophoresed and proteins were transferred
to PVDF membrane. Membrane was incubated with CD74
primary antibody (BD Pharmingen) and later incubated with
antirabbit HRP secondary antibody. The membrane was devel-
oped with ECL (GE Healthcare).
Serological analysis
For the detection of IgG and its isotypes in the serum, plates
were precoated with antimouse IgG, IgG1, IgG2a, IgG2b and
IgG3 (Bethyl Laboratories, Montgomery, Texas, USA), and sera
were applied at dilutions of 1:10 000 to 1:50 000. The assay
was developed with HRP-labelled goat antimouse IgG, IgG1,
IgG2a, IgG2b and IgG3 antibodies (Bethyl Laboratories). A
standard curve was derived with purified mouse IgG, IgG1,
IgG2a, IgG2b and IgG3 antibodies (Bethyl Laboratories). Serum
levels of IgM antibodies were detected using a similar method
as described above for IgG antibodies. Serum levels of IgG and
its isotype autoantibodies against dsDNA were determined by
specific ELISA as described.24 In brief, ELISA plates were coated
with poly-L-lysine and then with 1 mg/mL DNA (purified from
mouse tails after proteinase K digestion and isopropanol precipi-
tation) in SSC buffer. Next, the plates were incubated with
1:2000 diluted serum samples, and the assay was developed
with HRP-labelled goat antimouse IgG (Bethyl Laboratories).
Serum levels of IgM autoantibodies were detected using a
similar method as described above for IgG autoantibodies.
Antinuclear antibodies (ANA) were detected by indirect
immunofluorescence using HEp-2 cells as described.23 For the
detection of antibodies specifically against dsDNA, we used
Kallestad Crithidia luciliae substrate slides (Bio-Rad). C luciliae
is a single-cell organism possessing a giant mitochondrion con-
taining a highly condensed mass of circular dsDNA. This mass
of dsDNA, known as the kinetoplast, appears to be free of his-
tones or other mammalian nuclear antigens. It serves as a sensi-
tive and specific substrate for detecting autoantibodies to
dsDNA. Plasma levels of rheumatoid factor were estimated by
ELISA as described.25 For detection of antisheep IgG in the
serum, plates were coated with 100 mg/mL sheep IgG. Mouse
antisheep IgG was detected by goat anti-mIgG (Invitrogen,
Darmstadt, Germany).
Renal function analysis
Mouse albumin was estimated in urine samples using a Mouse
Albumin ELISA Quantitation set (Bethyl Laboratories). Mouse cre-
atinine was estimated in urine and serum samples using a
Creatinine FS kit (DiaSys Diagnostic Systems, Holzheim,
Germany). Mouse blood urea nitrogen was estimated in plasma
samples using a Urea FS kit (DiaSys Diagnostic Systems).
Glomerular filtration rate (GFR) was determined by clearance
kinetics of plasma fluorescein isothiocyanate-inulin (Sigma-Aldrich)
5, 10, 15, 20, 35, 60 and 90 min after a single intravenous bolus
injection. Fluorescence was determined with 485 nm excitation
and read at 535 nm emission. GFR was calculated based on a two-
compartment model using a non-linear regression curve-fitting
software (GraphPad Prism; San Diego, California, USA).
T cell activation assay
Bone marrow derived dendritic cells (DCs) were generated by
established protocols. DCs were stimulated with either normal
mouse serum or autologous serum for 24 h. CD4 T cells were
purified from whole splenocytes with anti-CD4 magnetic beads
(Miltenyi Biotec). DCs and T cells were cocultured (1:4 ratio)
for 48 h, and T cell activation was measured by flow cytometry
using anti-CD69 antibody (BD Biosciences).
Flow cytometry
Cell suspensions were stained with the following antibodies from
BD Pharmingen: antimouse CD3-FITC, CD4-APC, CD8-PerCP,
CD69-PE, CD11c-FITC, B220-Alexa Fluor 647, CD138-APC, k
Light Chain-PE, IgD-FITC, IgM-PE, CD40-FITC, CD21-FITC,
CD23-PE. The following antibodies were procured from Serotec
(Oxford, UK): F4/80-allophycocyanin and MHCII-FITC.
Real-time PCR
Total RNAwas isolated from spleen, lung and kidney tissue using
PureLink RNA Mini Kit (Invitrogen), and cDNA was synthesised
from 1 mg total RNA by using random hexamers and SuperScript
II Reverse Transcriptase (Invitrogen). SYBR Green I Dye detection
system was used for quantitative PCR (qPCR) on LightCycler 480
(Roche Diagnostics). The sequences of the gene-specific primers
(500 nM; Metabion, Martinsried, Germany) used are listed in
table 3. All reactions were performed in triplicate, and negative
controls contained no template DNA as described.26 We used 18S
rRNA as an endogenous control for normalisation. To verify that
the primer pairs produced only a single product, a dissociation
protocol was added after thermocycling, determining dissociation
of the PCR products from 60°C to 95°C. Data were analysed using
the comparative threshold cycle (ΔΔCt) method.
Statistical analysis
Data are expressed as means±SEM. The statistical differences
between two groups were performed using a Student t test, and
comparison of the three groups was performed using one-way
ANOVA. A p value≤0.05 was considered statistically significant.
All statistical calculations were performed using commercially
available statistical software GraphPad Prism.
RESULTS
Cathepsin expression in MRL-Fas(lpr) mice
First, we quantified the mRNA expression levels of those cathe-
psins that are involved in antigen presentation, that is, Cat B,
Table 1 In vitro enzyme inhibition assay
Cathepsin IC50
Human cathepsin S 0.4 nm
Mouse cathepsin S 0.5 nm
Human cathepsin K >25 mm
Human cathepsin L 49 mm
Human cathepsin B 44 mm
Human cathepsin V 1.3 mm
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Cat C, Cat D, Cat H, Cat L and Cat S, in kidneys and spleens of
6-, 10- and 14-week-old female MRL-Fas(lpr) mice by real-time
PCR. Age-matched and sex-matched MRL wildtype mice served
as controls. Among these cathepsins, only Cat S, Cat B and Cat
C were induced in kidney at 14 weeks of age (table 2). By con-
trast, all these cathepsins were induced in spleen starting from
10 weeks of age (see online supplementary figure S1B). In situ
hybridisation revealed predominant localisation of Cat S mRNA
expression to myeloid antigen-presenting cells, while the Cat S
mRNA signal was less dominant in CD20 B cells and clearly
absent in CD247 T cells in spleen, lung and kidney of female
MRL-Fas(lpr) mice (see online supplementary figure S2A). Cat S
immunostaining was consistent with that cell type-specific
expression pattern in spleen and lung, while in kidney epithelial
cells of proximal tubules stained positive in the absence of an
mRNA signal by in situ hybridisation, implying that Cat S
protein gets reabsorbed from the glomerular filtrate (see online
supplementary figure S2B). In the kidney, Cat S positivity was
also seen in dendritic cells of the tertiary lymphoid tissue
formed in the perivascular area of larger arteries (see online
supplementary figure S3). Together, Cat S is expressed in
antigen-presenting cells inside and outside of lymphoid tissues.
Pharmacodynamics and pharmacokinetics
of RO5461111 in mice
To test the functional contribution of Cat S in systemic auto-
immunity, we used the inhibitor RO5461111 (figure 1A).
RO5461111 is a potent and highly selective compound that
inhibits human Cat S with an IC50 of 0.4 nM and murine Cat S
of 0.5 nM (table 3). No submicromolar inhibition was detected
on any other of the tested cathepsins. In addition, RO5461111
showed ≤30% inhibition on a diversity panel consisting of
nearly 100 receptor binding and enzymatic assays at 10 μM con-
centration (data not shown). The ability of RO5461111 to
inhibit Cat S in cells was tested with the lip10 accumulation
assay in a human and mouse B cell line, and a potent induction
of lip10 was determined with EC50 of 17 and 8 nM, respect-
ively, (data not shown). In addition, RO5461111 dose-
dependently inhibited ovalbumin presentation of A20 cells to
ovalbumin-specific T cells, as quantified by IL-2 production (see
online supplementary figure S4). The acute pharmacodynamic
effect of RO5461111 was tested after oral gavage at doses from
0.1 to 100 mg/kg. Splenic induction of p10 was used as a
measure of enzyme inhibition. A strong p10 upregulation was
detected with maximal induction at low doses as 1 mg/kg
(figure 1B). Oral administration of RO5461111 by food admix
(262 mg/kg of food) to female MRL-(Fas)lpr mice resulted in an
exposure dose of 30 mg/kg and stable plasma levels of
RO5461111 at 400–600 ng/mL over a period of 8 weeks. This
was associated with a robust p10 fragment accumulation in the
spleen (figure 1C,D). Furthermore, oral treatment of C57BL/6
mice with RO5461111 suppressed T cell priming and antisheep
IgG upon vaccination with sheep IgG (figure 1E,F). Together,
RO5461111 is a specific small molecule Cat S antagonist with
favourable pharmacodynamic and pharmacokinetic profiles to
efficiently block Cat S over prolonged periods of time in mice,
which has the potential to suppress antigen-induced B and T cell
priming.
Table 3 Spleen and lymph node weight in MRL-Fas(lpr) mice
Vehicle R05461111 p Value by t test
Spleen 1.777±0.1152 1.505±0.1111 0.1026
Lymph node 2.369±0.2555 1.913±0.1509 0.1364




CCL2/MCP-1 NM_011333.3 F: 50-CCTGCTGTTCACAGTTGCC-30
R: 50-ATTGGGATCATCTTGCTGGT-30
IL-6 NM_031168 F: 50-TGATGCACTTGCAGAAAACA-30
R: 50-ACCAGAGGAAATTTTCAATAGGC-30
TNF NM_013693.2 F: 50-CCACCACGCTCTTCTGTCTAC-30
R: 50-AGGGTCTGGGCCATAGAACT-30
IL-12p35 NM_001159424.1 F: 50-CTAGACAAGGGCATGCTGGT-30
R: 50-GCTTCTCCCACAGGAGGTTT-30
18S rRNA NR_003278 F: 50-GCAATTATTCCCCATGAACG-30
R: 50-AGGGCCTCACTAAACCATCC-30
IL-10 NM_021274 F: 50-TGTCAAATTCATTCATGGCCT-30
R: 50-ATCGATTTCTCCCCTGTGAA-30
IL-1β NR_003278 F: 50-TTCCTTGTGCAAGTGTCTGAAG-30
R: 50-CACTGTCAAAAGGTGGCATTT-30
IL-23p19 NM_031252.2 F: 50-AATAATGTGCCCCGTATCCAGT-30
R: 50-GCTCCCCTTTGAAGATGTCAG-30












IL-12p40 NM_008352.2 F: 50-AGCAGTAGCAGTTCCCCTGA-30
R: 50-AGTCCCTTTGGTCCAGTGTG-30
April NM_001159505.1 F: 50-GTTGCTCTTTGGTTGAGTTGGG-30
R: 50-GTTGGATCAGTAGTGCGACAGC-30
BAFF NM_033622.1 F: 50-CCACCGTGCCTCTGTTTTTGC-30
R: 50-AGCCAACTGGTACAAGGACATCG-30
Taci NM_021349.1 F: 50-GGTCCAGGATTGAGGCTAAGTA-30
R: 50-GGAGAGTTTGCTTGTGACCCA-30
Cathepsin S NM_001267695.1 F: 50-AAGCGGTGTCTATGACGACCC-30
R: 50-GAGTCCCATAGCCAACCACAAG-30
Cathepsin B NM_007798.3 F: 50-GCAGGCTGGACGCAACTTCTAC-30
R: 50-GGTCTCTAATCTGTCCAATGGTCG-30
Cathepsin C NM_009982.4 F:
50-GAAGTTGGATACTGCCTACGACGAG-30
R: 50-CACATCATGGACCCACCCAGTC-30
Cathepsin D NM_009983.2 F: 50-CGCCTAAGACCACGGAGCCA-30
R: 50-ACTTATGGTGGACCCAGCAGGC-30
Cathepsin H NM_007801.2 F: 50-GCTGACCGTGAACGCCATAGA-30
R: 50-GCTGTACGTCTTTTGATGCTGTTTCA-30
Cathepsin L NM_009984.3 F: 50-GTGGACTGTTCTCACGCTCA-30
R: 50-TATCCACGAACCCTGTGTCA-30
Caspase 3 NM_009810.2 F: 50-TGCTGGTGGGATCAAAGC-30
R: 50-TGAATCCACTGAGGTTTTGTTG-30
Caspase 7 NM_007611.2 F: 50-CGGAATGGGACGGACAAAGAT-30
R: 50-CTTTCCCGTAAATCAGGTCCTC-30
Caspase 8 NM_009812.2 F: 50-TGCTTGGACTACATCCCACAC-30
R: 50-TGCAGTCTAGGAAGTTGACCA-30
BAD NM_007522.2 F: 50-AAGTCCGATCCCGGAATCC-30
R: 50-GCTCACTCGGCTCAAACTCT-30
BID NM_007544.2 F: 50-GCAAACCTTTGCCTTAGCC-30
R: 50-GTGTAGCTCCAAGCACTGCC-30
BAX NM_007527.3 F: 50-TGAAGACAGGGGCCTTTTTG-30
R: 50-AATTCGCCGGAGACACTCG-30
RIPK1 NM_009068.3 F: 50-GAAGACAGACCTAGACAGCGGA-30
R: 50-CAGTAGCTTCACCACTCGACTG-30
RIPK3 NM_019955.2 F: 50-CTGTCAAGTTATGGCCTACTGGTG-30
R: 50-GAACACGACTCCGAACCCTC-30
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Cat S blockade with RO5461111 reduces plasma levels
of IL-10 and TNF in MRL-(Fas)lpr mice
To test the effects of therapeutic Cat S inhibition in autoimmune
IC-GN, 12-week-old albuminuric female MRL-Fas(lpr) mice were
randomised to two groups that received either normal chow
(vehicle) or a food admix with RO5461111. Food intake and
weight gain were identical during the following 8 weeks until all
mice were sacrificed (data not shown). The same applied to spleen
and lymph node weights (see online supplementary table S2).
Plasma samples were obtained at baseline (12 weeks of age) and at
4 and 8 weeks of treatment (16 and 20 weeks of age). We first
measured IL-10 and IL-12p40 as major dendritic cell-derived cyto-
kines that promote B and T cell activation and proliferation,
respectively. Cat S blockade had significantly reduced IL-10 (not
IL-12p40) levels but only after 8 weeks of treatment (see online
supplementary figure S5A). Therefore, additional cytokines were
measured at 8 weeks only. Cat S blockade significantly reduced
TNF-α levels, while IL-2 and IFN-γ levels remained unaffected
(see online supplementary figure S5B). Thus, Cat S promotes the
systemic expression of IL-10 and TNF in MRL-(Fas)lpr mice,
which would predict a therapeutic effect on humoral immunity
and on tissue inflammation.
Cat S blockade with RO5461111 reduces the activation and
expansion of spleen dendritic cells, CD4, double-negative
T cells and plasma cells in MRL-(Fas)lpr mice
Next, we performed splenocyte flow cytometry on MRL-(Fas)
lpr mice at the end of the study. RO5461111 treatment reduced
the percentages of CD11c/MHCII+ and CD11c/CD40-activated
dendritic cells in MRL-(Fas)lpr mice (figure 2A). This was
Figure 1 Biochemical and pharmacological profiles of R05461111. (A) Chemical structure of R05461111. (B) Upregulation of invariant chain p10
levels in the spleen tissue was estimated by western blotting upon single-dose feeding of mice with different doses of R05461111 as indicated.
(C) Pharmacokinetics of R05461111 in female MRL-Fas(lpr) mice were determined by during the course of treatment from 12 to 20 weeks of age.
Plasma sampling was carried every two weeks, and R05461111 plasma levels were determined by modification of a sandwich hybridisation
procedure (n=5 for each time point). (D) Invariant chain p10 levels were estimated from spleen tissue using western blotting. (E) C57BL/6 mice were
fed R05461111 during the immunisation with sheep IgG. Spleen suspension flow cytometry analysis of the percentage of total CD3CD69 T cells,
CD3CD4CD69 T cells and CD3CD8CD69 T cells. (F) Antisheep IgG antibodies were estimated by ELISA. Data are expressed as means±SEM. *p<0.05,
**p<0.01, versus vehicle group (vehicle n=15, R05461111 n=15).
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associated with lower spleen mRNA expression levels for IL-1β,
IL-10, IL-23p19 and CXCL12, while the levels of IL-6,
IL-12p35, IFN-γ, TGF-β, CCL2 and CCL5 were not reduced
(figure 2B and see online supplementary figure S6). Less spleen
dendritic cell activation and cytokine expression may affect T
cell priming, which is anyway triggered by circulating lupus
autoantigens in these mice (see online supplementary figure
S7A). RO5461111 significantly reduced the amount of spleen
CD3 cells as well as activated (CD69) CD3 cells (figure 2C).
RO5461111 treatment significantly reduced CD4 cells and
CD4/CD8 double-negative T cells as well as activated (CD69)
CD4 T cells and (CD69) CD4/CD8 double-negative T cells
(figure 2D,E). In contrast to RO5461111’s effect on CD4 cells,
it did not affect the amount and activation stage of CD8 T cells
(figure 2F). Dendritic cells and activated T helper cells both
regulate antigen-specific B cell and plasma cell responses. The
inhibitor significantly reduced B220+CD69-activated B cells
while the expression of APRIL, BAFF and TACI remained
unaffected (figure 2G–I). Cat S blockade significantly reduced
the spleen mRNA levels of several cell death-related markers
such as RIPK1, caspase 3, caspase 7, BID and BAX (see online
supplementary figure S7B). However, RO5461111 treatment
Figure 2 Spleen qPCR and flow cytometry. Spleen cell suspensions were prepared for flow cytometry by using specific antibodies that identify
subsets of dendritic cells, T cells, B cells and plasma cells. (A) Fluorescence-activated cell sorting (FACS) analysis of total numbers of CD11c-positive
cells that were also positive for the activation markers MHC II or CD40. (B) Splenic mRNA expression levels of IL-1β, IL-10, IL-23p19 and CXCL12
were determined by real-time PCR. Data are expressed as mean of the ratio versus the respective 18S rRNA level±SEM. FACS analysis of the
percentage of total CD3 and CD3CD69 T cells (C), percentage of total double-negative and CD69 double-negative T cells (D), percentage of total
CD4 and CD4CD69 T cells (E) and percentage of total CD8 and CD8CD69 T cells (F). (G) FACS analysis of the percentage of total spleen B220+ and
B220+CD69 cells. (H) FACS analysis of the percentage of total spleen plasma cells. (I) Splenic mRNA expression levels of APRIL, BAFF/BlyS and TACI.
Data are expressed as mean percentages of all splenocytes±SEM (n=15 each treatment group). *p<0.05, **p<0.01, ***p<0.001, versus vehicle
group.
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significantly reduced the numbers of CD138 k Light chain+
plasma cells (figure 2H). Together, Cat S promotes the activa-
tion and expansion of spleen dendritic cells, CD4 T cells, B cells
and plasma cells in MRL-(Fas)lpr mice, a process blocked by
RO5461111.
Cat S blockade with RO5461111disrupts germinal
centres in MRL-(Fas)lpr mice
Systemic autoimmunity depends on the complex interaction of
myeloid cells and lymphocytes to promote the clonal selection
of autoreactive lymphocytes as well as Ig class switch and affin-
ity maturation of autoantibodies.1 4 27 These processes involve
PNA+ follicular B cells and takes place in the germinal centres
of the lymphoid tissue.4 Vice versa, disruption of germinal
centre formation counteracts autoimmunity.4 PNA revealed that
Cat S inhibition altered the distribution of follicular B cells away
from the germinal centre in lymphoid follicles to the perifollicu-
lar area in spleens of MRL-(Fas)lpr mice (see online
supplementary figure S8), implying that Cat S inhibition dis-
rupted the spatial organisation of germinal centres. This findings
was consistent with a RO5461111-related significant reduction
of spleen CXCL12 mRNA expression that is required for germi-
nal centre formation (figure 2B). Together, Cat S is required for
germinal centre formation in MRL-(Fas)lpr mice, which can be
suppressed by RO5461111.
Cat S blockade with RO5461111 reduces
hypergammaglobulinemia and lupus autoantibody
production in MRL-(Fas)lpr mice
B cell maturation and plasma cell expansion account for hyper-
gammaglobulinemia and the production of high-affinity IgG
autoantibodies in SLE. In vehicle-treated MRL-(Fas)lpr mice,
total IgG plasma levels increased from week 12 to 20 of age,
which mostly related to IgG1 and IgG2a (figure 3A).
RO5461111 treatment significantly reduced total IgG, IgG1,
IgG2a and IgG2b levels already after 4 weeks of treatment, but
there was a progressive decline of especially IgG1 and IgG2a
below baseline along treatment (figure 3A). In contrast, IgG3
and IgM levels remained unaffected (figure 3A,B). The
20-week-old MRL-(Fas)lpr mice displayed strong positivity for
ANA in a diffuse nuclear staining pattern consistent with the
presence of anti-DNA antibodies (figure 4A). This was validated
Figure 3 R05461111 reduces IgG antibodies in MRL-Fas(lpr) mice. (A) Plasma levels of total IgG and its isotypes IgG1, IgG2a, IgG2b and IgG3
were determined by ELISA. (B) Plasma levels of IgM antibodies were determined by ELISA. Data are expressed as means±SEM (n=15 each treatment
group). *p<0.05, **p<0.01, versus vehicle group.
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Figure 4 R05461111 reduces autoantibodies in MRL-Fas(lpr) mice. (A) Antinuclear antibodies (ANA) staining patterns on Hep2 human epithelial
cells for serum derived from vehicle-treated and R05461111-treated MRL-Fas(lpr) mice at 1:200 dilution. (B) Crithidia luciliae slides were incubated
with 1:50 diluted plasma of 20-week-old mice from both treatment groups, and autoantibody binding to the flagellate’s kinetoplast was detected
using an FITC-labelled goat antimouse IgG. Images on the left show anti-dsDNA IgG in green, and staining the kinetoplast DNA itself with DAPI
shown in blue is shown in the middle. The merged pictures are shown on the right side, demonstrating that FITC positivity matches with the
kinetoplast at the flagella pole of C luciliae. (C) Plasma levels of anti-dsDNA IgG and IgM antibodies were determined by ELISA. (D) Plasma levels of
IgG isotypes such as IgG1, IgG2a, IgG2b and IgG3 against ds-DNA were determined by ELISA. (E) Plasma levels of anti-RNP/Sm, antinucleosome
antibodies and rheumatoid factor were determined by ELISA. Data are expressed as means±SEM (n=15 each treatment group,). *p<0.05, **p<0.01,
***p<0.001 versus vehicle.
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by kinetoplast staining of the monocellular organism C luciliae
that contains pure double-stranded (ds) DNA (figure 4B). Cat S
blockade with RO5461111 drastically reduced ANA as well as
C luciliae kinetoplast positivity (figure 4A,B). Quantitative
assessment of anti-dsDNA IgG and IgM during the treatment
period confirmed that RO5461111 treatment reduced
anti-dsDNA IgG but not IgM plasma levels (figure 4C). This
effect on Ig class switch related to all subclasses of IgG (figure
4D). It is of note that Cat S blockade leads to a progressive
decline below baseline levels during the treatment period (figure
4D), suggesting that Cat S is needed to maintain autoantibody
production in existing clones of autoreactive plasma cells.
RO5461111 treatment also significantly reduced the plasma
levels of antinucleosome IgG, anti-smRNP IgG and rheumatoid
factor in MRL-(Fas)lpr mice, while the respective IgM autoanti-
bodies remains unaffected (figure 4E and see online
supplementary figure S9). Thus, Cat S drives hypergammaglobu-
linemia and the production of antinuclear IgG autoantibody
production in MRL-(Fas)lpr mice, a process that can be reversed
by RO5461111.
Cat S blockade with RO5461111 improves lupus nephritis
in MRL-(Fas)lpr mice
Lupus nephritis develops from intrarenal IC deposition and
local complement activation.3 Vehicle-treated 20-week-old
female MRL-Fas(lpr) mice displayed strong intraglomerular
IgG and complement C3c deposits, which was associated with
diffuse mesangial matrix expansion, profound mesangial cell
proliferation and focal segmental glomerulosclerosis (figure
5A). Cellular crescents and global glomerulosclerosis were
often seen. Most animals revealed profound tubulointerstitial
inflammation as characterised by periglomerular and diffuse
interstitial leucocyte infiltrates, tubular atrophy and intralum-
inal cast formation. Cat S blockade with RO5461111 signifi-
cantly reduced glomerular IgG and C3c deposits (figure 5B)
and the glomerular as well as the tubulointerstitial immuno-
pathology as quantified by the lupus nephritis activity index
that encompasses glomerular cell proliferation, matrix depos-
ition, leucocyte infiltration, focal necrosis, crescent formation
and tubulointerstitial inflammation. Treatment with
RO5461111suppressed lupus nephritis as documented by a
significant reduction of the nephritis chronicity index that
encompasses glomerular sclerosis, fibrous crescents, tubular
fibrosis and interstitial fibrosis (figure 5C). This improvement
of renal structure was associated with a significant reduction
of proteinuria and serum creatinine levels after 8 weeks of
treatment (figure 5D,E). GFR, as assessed by FITC-inulin
clearance kinetics at the end of the study, was severely
impaired in vehicle-treated MRL-Fas(lpr) mice but signifi-
cantly increased upon RO5461111 treatment (figure 5F).
These effects were associated with significantly reduced
mRNA expression levels of IL-1β, IL-6, IL-10 and IL-12p35,
while IFN-γ and TGF-β1 remained unaffected (see online
supplementary figure S10A). However, RO5461111 signifi-
cantly reduced the number of glomerular Mac-2+ macro-
phages and of activated dendritic cells (see online
supplementary figure S10B,D,E). Fluorescence-activated cell
sorting (FACS) analysis of kidney F4/80+ macrophages has
shown a trend towards less macrophages in the kidneys of
R05461111-treated mice (see online supplementary figure
S10C). Thus, Cat S contributes to the progression of lupus
nephritis in MRL-Fas(lpr) mice, a process that can be pre-
vented by RO5461111.
Cat S blockade with RO5461111 reduces lung inflammation
in MRL-(Fas)lpr mice
The lung is another organ frequently affected by systemic auto-
immunity in MRL-Fas(lpr) mice. Vehicle-treated MRL-Fas(lpr)
mice developed prominent peribronchial immune cell infiltrates
that compressed and destroyed lung tissue (figure 6A,B). Such
infiltrates were significantly decreased in 20-week-old
RO5461111-treated MRL-Fas(lpr) mice together with less mRNA
expression levels of IL-6, IL-12p40 and CCL2 (figure 6C), and
lower numbers of Mac-2+ macrophages (figure 6D). Thus, Cat S
also promotes pulmonary inflammation and damage in MRL-Fas
(lpr) mice. Obviously, late onset of RO5461111 therapy abrogates
autoantibody production and IC disease in MRL-Fas(lpr) mice.
DISCUSSION
The central role of MHC class II-mediated T and B cell priming
for autoimmunity and the non-redundant role of Cat S in
peptide loading and MHC class II assembly prompted us to
speculate that Cat S could be a potential therapeutic target for
SLE. Humoral autoimmunity develops from the presentation of
autoantigens in the context of costimulation, followed by an
expansion of autoreactive lymphocytes and the clonal selection
of high-affinity IgG autoantibody-producing plasma cells, a
process that takes place in the germinal centres of lymphoid fol-
licles.4 Our data confirm previously published reports that Cat S
inhibition interferes with all of these processes upon vaccination
with foreign or self-antigens,10 19 most likely by limiting
Ii-dependent peptide loading into MHC class II. The novel
aspects of our study are threefold. First, here we report a novel
Cat S antagonist that is potentially suitable for therapy in
humans. Second, we first document the contribution of Cat S in
lupus-like spontaneous systemic autoimmunity and antinuclear
antibody production. This process specifically involves priming
of CD4 T cell subsets (but not CD8 T cells) and affinity matur-
ation towards IgG autoantibody-producing plasma cells within
germinal centres. Third, Cat S blockade initiated as late upon
‘clinically’ detectable signs of lupus nephritis, such as protein-
uria and/or elevated serum creatinine, was effective in suppres-
sing hypergammaglobulinemia and autoantibody production
below baseline and in preventing lupus nephritis progression.
Cat S inhibition with the novel, orally available, and highly
selective Cat S inhibitor RO5461111 was effective in vivo and
had profound effects on the lupus-like systemic autoimmunity
that spontaneously develops in MRL-Fas(lpr) mice. The most
striking therapeutic effect was the suppression of IgG but not
IgM (auto-)antibody production, which was consistent for all
ANA specificities tested. This effect on Ig class switch implies
that Cat S contributes to the affinity maturation of the respective
antibody-producing cells, which was consistent with a significant
suppression of spleen plasma cells upon Cat S inhibition.
Affinity maturation takes place in the germinal centres of lymph-
oid follicles and requires an orchestrated interaction of antigen-
presenting cells and lymphocytes such as follicular dendritic
cells, follicular B cells and antigen-specific CD4 T helper cells.4
Cat S inhibition disrupted the typical spatial organisation of the
germinal centres in MRL-Fas(lpr) mice, as was reported by pre-
vious vaccination studies using Cat S-deficient mice or less
selective Cat S antagonists.8 15 22 Obviously, compromising
appropriate MHC class II assembly is sufficient to impair germi-
nal centre formation, for example, by suppressing CXCL12
expression, a factor needed for the spatial organisation of fol-
licular B cells to the dark zone of germinal centres and their
maturation towards plasma cells that produce high-affinity IgG
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autoantibodies.28 29 By contrast, Cat S is not involved in
peptide loading to MHC class I; hence, Cat S inhibition did not
affect CD8 T cells in MRL-Fas(lpr) mice. This implies that thera-
peutic Cat S inhibition spares MHC I-mediated and CD8 T cell-
mediated immunity, which should reduce the risks of
therapy-associated infections as compared with global immuno-
suppressants such as steroids, cyclophosphamide or mycopheno-
late mofetil. Of note, we did not observe any infectious
complications in the mice studied with the Cat S inhibitor.
We designed our study also to test the therapeutic potential of
Cat S inhibition; hence, treatment was initiated not before ‘clin-
ically’ detectable signs of autoimmune tissue injury, such as pro-
teinuria and/or elevated serum creatinine, became evident. It is
of note that Cat S inhibition suppressed hypergammaglobuline-
mia and autoantibody production below the baseline levels, con-
sistent with a reversal of the underlying systemic autoimmune
process.30 However, at the tissue level, Cat S inhibition was
effective only in terms of preventing a further increase in serum
Figure 5 R05461111 suppresses renal pathology in MRL-Fas(lpr) mice. (A) Renal sections of 20-week-old MRL-Fas(lpr) mice were stained with
antibodies for IgG and complement C3c as indicated. Note that inhibitor-treated mice show less glomerular IgG and C3c deposits. Renal sections of
20-week-old MRL-Fas(lpr) mice were stained with periodic acid–schiff (PAS). Representative PAS staining kidney sections showed glomerular damage
in vehicle-treated mice compared with inhibitor-treated mice. Images are representative for 15 mice in each treatment group. Magnification, ×400 or
×200. (B) Quantitative measures of lupus nephritis in MRL-Fas(lpr) mice. (B) Glomerular IgG and complement C3c deposition was compared
between vehicle-treated and inhibitor-treated groups (score ranging from 0 to 3). (C) The lupus nephritis disease activity index (scores ranging from
0 to 24) and the lupus nephritis chronicity index (scores ranging from 0 to 12) were determined as markers of kidney damage in lupus nephritis.
Renal functional parameters like proteinuria (D), plasma creatinine (E) and glomerular filtration rate (F) were determined from 15 mice in each
treatment group at 20 weeks of age. Data are expressed as means±SEM. *p<0.05, **p<0.01, versus vehicle group (vehicle n=15, R05461111
n=15).
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creatinine, which implies a stabilisation of renal function and
not a reversal of tissue remodelling. Even when admitting that
the reversal of tissue remodelling may take more time than we
studied here, our data would favour to initiate Cat S blockade at
an early stage of SLE to normalise aberrant immunity and to
prevent disease progression.
In summary, Cat S is a non-redundant mediator of SLE because
it is required for the assembly of MHC class II molecules with
autoantigenic peptides. Interfering with this process disturbs ger-
minal centre formation, that is, the expansion and activation of
CD4 T cells, as well as the activation and maturation of autoreac-
tive B cells and subsequent production of high-affinity IgG auto-
antibodies. Vice versa, therapeutic Cat S inhibition reverts the
aberrant autoimmune response and protects from progressive
lupus nephritis. This therapeutic intervention that spares CD8 T
cell-mediated adaptive immunity holds the potential to avoid the
unfavourable side effects of unselective immunosuppressive drugs
currently used for the treatment of SLE.
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